AzTrials
AzTrials

AnesthesiaPhase 4NCT02237443

Mask Ventilation Before and After Neuromuscular Blockade

A Phase 4 study testing Rocuronium, Vecuronium Bromide and Succinylcholine in people with Anesthesia, run by University of Washington at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Anesthesia providers are taught to "test" that they can properly ventilate a patient's lungs before administering a neuromuscular blocking drug (NMBD), rendering the patient apneic. This is a traditional teaching, not based on empirical evidence. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Anesthesia
What is being tested?
Rocuronium, Vecuronium Bromide and Succinylcholine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
210 participants
Where
1 siteUnited States
Study dates
Aug 2014to Feb 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients who are 18 years or greater
  • Present for elective surgery and
  • Require placement of a breathing tube for their surgery

Who cannot join

  • Patients will not be eligible if they are pregnant
  • Are a minor
  • Are a prisoner
  • Have impaired decision-making capacity
  • Have symptomatic untreated reflux
  • Prior esophagectomy or hiatal hernia
Show all 10Show fewer
  • Vomiting within 24 hours of surgery
  • Known oral or facial pathology making a proper mask fit unlikely
  • Any condition for which the primary anesthesia team deems a rapid-sequence intubation to be appropriate
  • Prior allergy or contraindication to receiving rocuronium, vecuronium, or succinylcholine.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Harborview Medical Center

    Seattle, Washington, 98104

Other trials in United States

About this study

Official title: Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial

Anesthesia providers are taught to "test" that they can properly ventilate a patient's lungs before administering a neuromuscular blocking drug (NMBD), rendering the patient apneic. This is a traditional teaching, not based on empirical evidence. The investigators primary hypothesis is that ventilation after the administration of NMBDs is non-inferior with that before their administration with respect to the composite safety endpoint of inadequate (MVi) and dead-space only (Vds) ventilation.

Read the detailed description

The following will be carried out per routine standard of care:

The patient will be met in the pre-operative area by the attending anesthesiologist who interviews and examines the patient. A full explanation of the general anesthetic including risks and benefit will be given. Patients will be premedicated with 1-2 mg of midazolam at the discretion of the attending anesthesiologist. Once in the OR, standard American Society of Anesthesiology (ASA) monitors are established. At a minimum, this includes non-invasive monitoring of blood pressure by automated cuff, oxygen saturation via pulse oximetry, heart rate and rhythm by 3-lead continuous electrocardiographic tracing, core body temperature, expired carbon dioxide concentration, and depth of neuromuscular blockade when paralytic medications are used. Additional monitoring may be applied as deemed appropriate by the attending anesthesiologist on a case-by-case basis. At this time, the patient is given fentanyl 1-2 mcg/kg. After a period of breathing 100% oxygen by facemask (typically for 3 minutes or until the anesthesia monitor shows the exhaled concentration of oxygen to be >80%) and when the primary anesthesia team judges denitrogenation to be sufficient, anesthesia will be induced intravenously with propofol 2-3 mg/kg. Once the patient is unresponsive to a jaw thrust, the patient is ventilated via a facemask. If the anesthesia provider feels that ability to move air in and out of the patients lungs is difficult, the may reposition the mask on the patient's face, reposition the head, neck, or shoulders of the patient, or place a plastic oropharyngeal airway to maintain the mouth in an open position and to help keep the base of the tongue from obstructing the upper airway. A drug that causes muscle paralysis is given, which takes 1-5 minutes to work depending on the drug administered; during this period the patient continues to be ventilated by facemask. However, there is not standard for the timing of administration of the paralytic drugs as some anesthesia providers administer them near simultaneous to the administration of the other drugs used to induce anesthesia. Often, during this time, an inhaled anesthetic agent is started to avoid any gaps in the effect of the intravenous medications. Once the muscle relaxant works, a breathing tube is placed in the patient's windpipe, and ventilation occurs via the tube connected to a breathing machine.

The study deviates from the standard anesthesia care described above in the following ways:

Before the patient arrives in the operating room, a small plastic device called a pneumotachograph will be placed in-line between the facemask and the breathing circuit of the anesthesia machine. This allows measurements of airway pressure and volumes to be recorded in an accurate manner and later sent electronically to a computer for analysis. The in-line portion of the device is no larger than a typical circuit connector already used and does not hinder the performance of the anesthesia provider in any way. After routine intravenous induction, once the patient is unresponsive to a jaw thrust patients will be ventilated by facemask for 60 seconds. Breaths will be delivered using the breathing bag of the anesthesia circuit as would otherwise be performed. The airway managers will be asked to follow a treatment algorithm to resolve any difficulty encountered in providing mask ventilation. This algorithm represents common practice. After the initial 60 seconds, the medication to induce muscle paralysis will be given. A nerve stimulator placed on the patients wrist will then be turned on and will indicate when the medication has taken full effect and the patient is paralyzed. During this period of time, approximately 60-90 seconds, with the patients unconscious and apneic, their breathing will be supported as would otherwise be done. Post-paralysis, data collection will again begin and the anesthesia provider will start again breathing for the patient via a facemask as described in figure 2 for another 60 seconds. The operator will be blinded to the display on the ventilator machine, which provides information about the amount of air going in and out of the patients lungs, but will be able to monitor the patient's pertinent vital signs on the anesthesia machine. At all times, one member of the primary anesthesia team will have full access to all monitoring as would normally take place. After this time, the tracheal tube will be placed for the surgery.

Appropriate sizing of the adult facemask and oropharyngeal airway will be determined by the primary anesthesia team. All breaths will be delivered by hand ventilation using the breathing bag of the anesthesia machine. The returned tidal volume will be recorded for each minute of the study period from the pneumotachograph placed inline with the anesthesia circuit at the level of the mask/elbow connector interface as described above. The total time from induction to placement of a breathing tube will be 4-5 minutes and represents an additional minute of "study" time to the standard care. This timing was chosen as the investigators feel that it will provide sufficient information about ventilation volumes without unduly prolonging the anesthetic.

The study coordinator will remain in the room for the actual intubation to record its ease or difficulty per the report of the primary anesthesia provider. The act of placing the breathing tube is not part of the study protocol, however.

Data points to be collected:

Data regarding tidal volume, minute ventilation, airway pressures, and end-tidal carbon dioxide will be recorded directly by the in-line pneumotachograph and then loaded into an excel spreadsheet. No manual data collection will be necessary.

Data and Safety Monitoring Plan

The study may be terminated by the primary anesthesia team if the one or more of the following criteria are met:

  1. Inadequate ventilation by clinical criteria (inadequate chest rise, no fogging in the mask, no positive tracing of end-tidal carbon dioxide and/or lack of measurable returned tidal volumes on).
  2. Low oxygen saturation (< 90%).
  3. If for any reason, the primary anesthesia team feel that in their clinical judgment, immediate tracheal intubation is warranted.

All unanticipated problems and adverse event will be recorded in the study sheet by a study coordinator. At the earliest time, each unanticipated problem and adverse event will be examined by at least 2 study investigators. In the event of an unanticipated problem of adverse effect (eg inadequate mask ventilation), back-up will be provided by the primary anesthesia team caring for the patient and may include placing a laryngeal mask airway or a surgical airway. These are the same provisions that would be made for any non-study case as mask ventilation by using one or two hands represents standard practice.

Statistical Considerations:

The investigators are aiming to show that administration of a neuromuscular blocking agent is "safe" with respect to mask ventilation. In other words, that the average exhaled tidal volume per breath over one minute after the administration of a NMBD will be non-inferior to that measured before their administration. At the time of the planning of this study, no studies had reported a mean±SD for tidal volumes before and after NMBDs. However, based upon a prior comparative trial of two different mask-hold techniques, the standard deviation (SD) of the average exhaled tidal volume after induction of anesthesia, using the anesthesia ventilator and a two-hand jaw-thrust mask hold technique was 130 mL. With the equivalence limit, d, set as 50 mL per breath, with a significance level (α) of 2.5% and a power (1-β) of 95%, a total sample size of 208 patients per group (before and after NMBD for a total sample of 416 study periods) were required. In other words, if there is truly no difference between the mask ventilation before and after NMBD, then 208 patients, each as their own control, are required to be 95% sure that the limits of a 2-sided 95% confidence interval will exclude a difference in means of >50 mL.

Conditions
Anesthesia
Being tested
Rocuronium, Vecuronium Bromide, Succinylcholine
Keywords
Patient Safety

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RocuroniumDrug

    Administration of a NMBD

  • Vecuronium BromideDrug

    Also called Vecuronium

    Administration of a NMBD

  • SuccinylcholineDrug

    Also called Sux

    Administration of a NMBD

Study groups in NCT02237443
Study groupRoleWhat they receive
Post-inductionOtherAnesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
Receives: Drug: Rocuronium; Drug: Vecuronium Bromide; Drug: Succinylcholine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average exhaled title volumes

    The difference in average exhaled volumes per breath between study periods before and after neuromuscular blocker administration.

    Measured: 2 minutes

Secondary outcomes (4)
  1. Minute ventilation (VE)

    The total amount of gas exhaled per minute (the sum of all exhaled Vt over the study period)

    Measured: 2 minutes

  2. Warter's scale

    Clinico-physiologic scale for assessment of the difficulty of mask ventilation

    Measured: 2 minutes

  3. Han's scale

    Clinical scale for assessment of the difficulty of mask ventilation

    Measured: 2 minutes

  4. Composite of difficult/impossible mask ventilation

    The composite of difficult mask ventilation (DMV)/impossible mask ventilation (IMV) by Warter's scale and a volume definition of < 4 ml/kg predicted body weight or < 150 mL in total per breath on average

    Measured: 2 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2014 (estimated)
  2. Study startAug 2014
  3. Primary completionNov 2014
  4. Study completionFeb 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
210 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02237443
Sponsor's protocol ID
40262-D
Status last verified
Apr 2015
First submitted
28 Aug 2014
Last updated
9 Apr 2015
Results posted
No
Data monitoring committee
No

Publications

  • Joffe AM, Ramaiah R, Donahue E, Galgon RE, Thilen SR, Spiekerman CF, Bhananker SM. Ventilation by mask before and after the administration of neuromuscular blockade: a pragmatic non-inferiority trial. BMC Anesthesiol. 2015 Oct 6;15:134. doi: 10.1186/s12871-015-0111-z.

    PubMed 26444853

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Rocuronium, Vecuronium Bromide and Succinylcholine in people with Anesthesia, run by University of Washington at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average exhaled title volumes (time frame: 2 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02237443, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in